• Explore /
  • Poster
  • / Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) <i>KRAS</i> exon 2 and WT <i>RAS</i> metastatic colorectal cancer (mCRC).

Final results from a phase III trial evaluating panitumumab (pmab) + best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

null

Tae Won Kim

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

Tae Won Kim , Anneli Elme , Zvonko Kusic , Joon Oh Park , Anghel Adrian Udrea , Sun Young Kim , Joong Bae Ahn , Ricardo Villalobos Valencia , Krishnan Srinivasan , Ante Bilic , Nebojsa Manojlovic , Jun Dong , Xuesong Guan , Catherine Lofton-Day , A. Scott Jung , Eduard Vrdoljak

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT01412957

Citation

J Clin Oncol 34, 2016 (suppl; abstr 3536)

DOI

10.1200/JCO.2016.34.15_suppl.3536

Abstract #

3536

Poster Bd #

233

Abstract Disclosures

Similar Posters

First Author: Tae Won Kim

First Author: Marc Peeters

First Author: Kelly S. Oliner

First Author: K. Oliner